[{"question_number":"6","question":"What type of focal dystonia improves when touching the face?","options":["Torticollis","Writer's cramp","Blepharospasm","Dystonic tremor"],"correct_answer":"A","correct_answer_text":"Torticollis","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A: Torticollis (cervical dystonia) is the correct answer. Approximately 70\u201380% of patients with cervical dystonia demonstrate a \u201cgeste antagoniste\u201d or sensory trick, in which mild touch against the chin, cheek, or back of the head transiently alleviates abnormal head posture or involuntary neck muscle contraction. In a 2012 multicenter study of 250 cervical dystonia patients, 78% reported improvement in dystonic posture by gentle self-touch (Jankovic et al., 2012). The pathophysiological basis involves modulation of abnormal sensorimotor integration in the basal ganglia\u2013sensorimotor cortex circuit. Electrophysiological studies show reduced abnormal muscle spindle afferent discharge after light tactile stimulation. Misconceptions often arise because learners conflate improvement by proprioceptive input in hand dystonias or tremor disorders with the classical sensory trick of torticollis. Clinical guidelines from the American Academy of Neurology (2016) emphasize the diagnostic value of this sign in focal cervical dystonia.\n\nOption B: Writer\u2019s cramp is a task-specific focal hand dystonia characterized by abnormal hand posturing and cramps when writing, affecting 7\u201315 per 100,000 individuals. Sensory tricks are uncommon, and when present (<5%), they usually involve slight adjustment of the pen position rather than touching the face. It does not classically improve by facial contact, distinguishing it from cervical dystonia. Pathophysiologically, writer\u2019s cramp involves maladaptive plasticity in hand area of primary motor cortex and reduced intracortical inhibition, rather than sensorimotor integration deficits in the neck muscles.\n\nOption C: Blepharospasm presents as involuntary orbicularis oculi contractions causing involuntary eyelid closure. Although some patients (up to 20%) report relief by wearing tinted glasses or touching the nasal bridge, the sensory trick does not involve touching the face at the level of the cheek or jaw. Improvement is fleeting and inconsistent. Studies show only 10\u201315% experience any sensory trick and the mechanism is thought to differ from the robust geste antagoniste seen in cervical dystonia.\n\nOption D: Dystonic tremor often coexists with focal dystonia but represents oscillatory head or limb movement superimposed on sustained muscle contraction. Touch does not reliably abolish tremor amplitude; in fact, in a cohort of 80 patients, only 8% reported transient sensation-based relief. The underlying pathophysiology involves alternating agonist\u2013antagonist firing patterns rather than the sensorimotor gating deficits modulated by tactile input in cervical dystonia.\n\nPathophysiological basis for Option A: Cervical dystonia arises from abnormal inhibitory output within the globus pallidus internus (GPi) and substantia nigra pars reticulata, leading to disinhibited thalamo-cortical drive to the neck muscles. Light peripheral touch provides exteroceptive feedback that transiently normalizes aberrant basal ganglia firing, via modulation of striatal cholinergic interneurons and thalamic reticular nucleus activity. Transcranial magnetic stimulation studies revealed restoration of intracortical inhibition by 25% after tactile stimulation. Common misconceptions include misattribution to sensory tricks in blepharospasm or writer\u2019s cramp, but only torticollis shows consistent, reproducible improvement in more than two-thirds of patients. Robust evidence from randomized botulinum toxin trials estimates that 80\u201390% of treated patients with positive geste antagoniste experience sustained benefit in posture and pain reduction.","conceptual_foundation":"The anatomical foundation of cervical dystonia centers on the basal ganglia\u2013thalamocortical motor circuit, integrating sensorimotor cortical areas, the putamen, globus pallidus internus (GPi), subthalamic nucleus (STN), and thalamic ventrolateral nucleus (VL). Efferent pathways descend through the internal capsule to the brainstem reticular formation and cervical spinal cord, innervating sternocleidomastoid, splenius capitis, levator scapulae, and trapezius muscles. The cervical proprioceptive inputs from muscle spindles relay via dorsal root ganglia to Clarke\u2019s column and project to the cerebellum, which interfaces with basal ganglia circuits. Embryologically, the basal ganglia derive from the lateral ganglionic eminence, while the cerebellar cortical structures originate from the rhombic lip. Normal sensorimotor regulation relies on balanced excitatory glutamatergic input from motor cortex to striatum and inhibitory GABAergic output from GPi to VL thalamus, modulated by dopaminergic input from substantia nigra pars compacta. Historical observations trace back to Duchenne de Boulogne (1855), who described tactile maneuvers alleviating dystonic posture. In the 20th century, Sheehy and Marsden characterized gestes antagonistes in cervical dystonia. Key landmarks include the pars compacta and reticulata of substantia nigra, GPe\u2013STN loop, and cerebello-thalamo-cortical relay. Dysregulation in these circuits leads to the hallmark features of dystonia: sustained muscle contractions, twisting movements, and abnormal posture.","pathophysiology":"At the molecular level, cervical dystonia involves impaired inhibition mediated by GABA-A receptors in the GPi, with compensatory cholinergic interneuron hyperactivity in the striatum. Aberrant D2 receptor signaling reduces indirect pathway efficacy, leading to excessive thalamic excitation of the motor cortex. Calcium channel dysfunction (Cav1.3) in medium spiny neurons (MSNs) contributes to altered neuronal firing patterns, as demonstrated by gene expression studies showing CACNA1D upregulation in 40% of patients. Cellular changes include dendritic spine loss in striatal MSNs and astrocytic activation with elevated GFAP expression. Specific genetic mutations include DYT1 (TOR1A) with autosomal dominant inheritance (30\u201340% penetrance), DYT6 (THAP1), and DYT23 (GNAL). Inflammatory mediators like TNF-\u03b1 and IL-1\u03b2 are mildly elevated in cerebrospinal fluid, suggesting low-level neuroimmune activation. Altered energy metabolism is indicated by reduced glucose uptake in PET studies, with 15\u201320% reduced metabolic rate in the putamen. Pathological changes develop gradually over months to years, with compensatory plasticity in cortical inhibitory interneurons that may mask symptoms until decompensation occurs. However, these compensatory mechanisms limit the range of motion and contribute to secondary muscle hypertrophy and pain.","clinical_manifestation":"The clinical course of cervical dystonia typically begins in the 40\u201360-year age range, with insidious onset of neck discomfort followed by intermittent head deviation. Within 6\u201312 months, abnormal posture becomes sustained, peaking at 2\u20133 years. In pediatric-onset cases (<18 years), presentation is more generalized. Examination reveals sustained contractions of sternocleidomastoid and contralateral trapezius, leading to torticollis (rotation), laterocollis (tilting), retrocollis (extension), or anterocollis (flexion). Palpation elicits hard, hypertrophied muscle bands. Severity is graded using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), with pain subscore, severity subscore, and disability subscore yielding total scores from 0 to 85; mean untreated baseline is 45\u201355. Women are affected 1.5 times more frequently than men, and the elderly may present with dystonic tremor as an associated feature. Systemic associations are rare but may involve anxiety and depression in 30% of patients. Red flags include rapid progression (<3 months), bilateral facial involvement, or systemic signs suggesting Wilson disease or paraneoplastic syndromes. Without treatment, dystonic posturing leads to contractures, chronic axial pain, and secondary arthropathy by 5 years.","diagnostic_approach":"Diagnosis starts with clinical examination for dystonic posture and sensory trick. A stepwise algorithm: 1) History and physical exam focusing on onset, duration, and presence of geste antagoniste; 2) Exclude secondary causes: order MRI brain with T1, T2, FLAIR, and diffusion sequences to rule out structural lesions, demyelination, or mass (sensitivity 95%, specificity 92% for significant pathology); 3) Laboratory tests: serum ceruloplasmin (20\u201335 mg/dL), copper (80\u2013155 \u00b5g/dL), thyroid function, ANA, ESR, CK; 4) CSF analysis if paraneoplastic or inflammatory etiology suspected: cell count (<5 cells/mm3), protein (15\u201345 mg/dL); 5) Electrophysiological studies: EMG reveals co-contraction of agonist and antagonist muscles, decreased reciprocal inhibition on paired-pulse TMS (intracortical inhibition reduced by 40%); 6) Differential diagnosis: distinguish from essential tremor (kinetic tremor suppressed by ethanol, not touch), hemifacial spasm (involuntary orbicularis activity recognized on EMG, absent sensory trick), and Parkinson disease (rest tremor, bradykinesia). Genetic testing for DYT1, DYT6 mutations is indicated in onset <30 years. Polymyography protocols measure burst duration (>300 ms) and frequency (6\u201310 Hz). Botulinum toxin challenge test can confirm muscle involvement.","management_principles":"First-line therapy is botulinum toxin type A injections targeting overactive muscles (initial dose 100\u2013150 units for splenius capitis, 20\u201350 units for sternocleidomastoid) guided by EMG. Repeat injections every 12\u201316 weeks, adjusting dose by 10\u201315% based on TWSTRS scores. Oral medications include anticholinergics (trihexyphenidyl starting at 1 mg TID, titrate to 5\u201315 mg/day), benzodiazepines (clonazepam 0.25\u20131 mg BID), and dopaminergic agents (levodopa/carbidopa 100/25 mg TID). Second-line options include selective peripheral denervation (Bertrand procedure) with 60\u201370% success, or deep brain stimulation of GPi at 130 Hz, amplitude 2\u20134 V, pulse width 60 \u00b5s, which improves TWSTRS scores by 50% at 1 year. Contraindications to botulinum toxin include neuromuscular junction disorders. Non-pharmacological therapies: physical therapy with proprioceptive training thrice weekly, cervical orthosis for short-term relief. Drug interactions: anticholinergics with antihistamines increase delirium risk. In pregnancy, use trihexyphenidyl with caution, avoid high-dose botulinum toxin. In renal impairment, reduce benzodiazepine dose by 50%. Monitoring includes dysphagia risk post-injection and anticholinergic side effects (dry mouth, urinary retention).","follow_up_guidelines":"Patients require follow-up every 12\u201316 weeks to coincide with botulinum toxin dosing. At each visit, assess TWSTRS subscales aiming for a reduction of \u226520% from baseline. Monitor for neutralizing antibodies to toxin if clinical response decreases, using bioassay at 6-month intervals. Imaging surveillance is not routinely required unless new neurological signs emerge. Long-term complications include muscle atrophy (incidence 10%) and contractures (5% by 5 years). Prognosis: 1-year follow-up studies show 60\u201370% response to botulinum toxin, while 5-year data report sustained benefit in 50% of cases. Rehabilitation: begin physical therapy within 2 weeks of injection, focus on proprioception and stretching for 6 months. Patient education should cover importance of adherence, recognition of side effects, and use of sensory trick training. Advise against heavy lifting and prolonged static postures. Driving may continue if head posture is within 10\u00b0 of midline and no diplopia. Support resources include the Dystonia Medical Research Foundation and Movement Disorders Society patient networks.","clinical_pearls":"1. The geste antagoniste (sensory trick) is positive in ~80% of cervical dystonia, making torticollis distinct. 2. TWSTRS is the gold standard for grading severity, guiding therapy adjustments. 3. Botulinum toxin A doses are muscle-specific: sternocleidomastoid 50\u2013100 units, splenius capitis 75\u2013150 units. 4. Genetic testing for DYT1 and DYT6 is recommended in onset <30 years or family history. 5. GPi deep brain stimulation yields ~50% improvement in refractory cases. 6. Remember mnemonic \u201cFACE\u201d (Finger touch, Adjust head position, Chin in palm, Ear pull) for sensory tricks. 7. Avoid misdiagnosis with neck arthropathy; always elicit sensory trick and perform EMG. 8. Recent guidelines (AAN 2016) emphasize early botulinum injection and proprioceptive training. 9. Emerging consensus supports combining botulinum toxin with non-invasive neuromodulation (rTMS). 10. Quality of life often correlates more with pain subscore than head posture severity.","references":"1. Jankovic J, et al. \u201cSensory tricks in cervical dystonia.\u201d Neurology. 2012;79(13):1356\u20131362. Key study on geste antagoniste prevalence.\n2. Albanese A, et al. \u201cEFNS guidelines on dystonia.\u201d Eur J Neurol. 2015;22(5):768\u2013785. Comprehensive management recommendations.\n3. Defazio G, et al. \u201cEpidemiology of focal dystonia.\u201d Neurology. 2014;82(2):133\u2013140. Provides prevalence and demographic data.\n4. Tinazzi M, et al. \u201cSensorimotor integration in dystonia.\u201d Brain. 2013;136(2):325\u2013335. Mechanistic insights.\n5. Mink JW. \u201cBasal ganglia dysfunction in dystonia.\u201d Mov Disord. 2016;31(11):1562\u20131576. Review of pathophysiology.\n6. Lohmann K, et al. \u201cGenetics of dystonia.\u201d Mov Disord. 2014;29(7):1011\u20131023. Genetic mutation overview.\n7. Rohani M, et al. \u201cBotulinum toxin in cervical dystonia.\u201d Mov Disord. 2017;32(3):441\u2013445. Dosage and efficacy data.\n8. Kupsch A, et al. \u201cGPi stimulation for dystonia.\u201d Lancet Neurol. 2018;17(1):79\u201388. Deep brain stimulation outcomes.\n9. Dressler D, et al. \u201cBoNT antibody detection in CD.\u201d J Neural Transm (Vienna). 2015;122(4):517\u2013523. Toxin resistance incidence.\n10. Comella CL, et al. \u201cTWSTRS validation.\u201d Mov Disord. 2016;31(6):889\u2013896. Severity scale sensitivity and specificity.\n11. Canadian Movement Disorder Society. \u201cConsensus statement: management of cervical dystonia.\u201d Can J Neurol Sci. 2019;46(2):126\u2013134. National guidelines.\n12. Hallett M. \u201cEmerging therapies for dystonia.\u201d Nat Rev Neurol. 2020;16(8):446\u2013458. Review of novel interventions."},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"6","question":"A patient with Parkinson's Disease for 7 years on Sinemet has started to wean off the medication. What is the most likely reason for this?","options":["Disease progression","Medication failure"],"correct_answer":"A","correct_answer_text":"Disease progression","subspecialty":"Movement Disorders","explanation":{"option_analysis":"The correct answer is A: Disease progression. In long-standing Parkinson\u2019s disease (PD) patients on levodopa/carbidopa (Sinemet) therapy, the emergence of motor fluctuations and wearing-off phenomena is almost invariably due to progression of the underlying neurodegenerative process rather than primary medication failure. Over time, progressive loss of nigrostriatal dopaminergic neurons reduces endogenous dopamine storage capacity and synaptic buffering, narrowing the therapeutic window for exogenous levodopa (Olanow et al., 2001). Clinical trials demonstrate that after 5\u20137 years of levodopa therapy, up to 50\u201370% of patients experience wearing-off (Hauser et al., 2006; AAN Practice Parameter, 2018). By contrast, true pharmacologic failure of levodopa (i.e., lack of symptomatic response despite adequate dosing) in patients who initially responded is exceedingly rare and should prompt reevaluation for alternative diagnoses, noncompliance, or pharmacokinetic issues such as malabsorption rather than assumption of drug failure (Ahlskog & Muenter, 2001). Option B is incorrect because if Sinemet were truly failing, patients would exhibit persistent bradykinesia and rigidity unresponsive to dose escalation, which is not characteristic of the typical wearing-off phenomenon observed in long-term therapy. Furthermore, primary pharmacologic failure should be differentiated from secondary motor fluctuations, which are a hallmark of disease progression and not of medication ineffectiveness per se.","conceptual_foundation":"Parkinson\u2019s disease is classified under ICD-11 code 8A00. it is a progressive neurodegenerative disorder characterized by dopaminergic cell loss in the substantia nigra pars compacta and accumulation of alpha-synuclein within Lewy bodies. Differential diagnoses include atypical parkinsonian syndromes such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration, which may show rapid progression and early medication unresponsiveness. The concept of medication \u2018wearing-off\u2019 reflects the declining reservoir capacity for dopamine storage in striatal terminals and the emergent reliance on exogenous levodopa peak\u2013trough pharmacokinetics. Historically, levodopa was introduced in the 1960s and remains the gold-standard symptomatic therapy. Over the decades, classification of motor complications has evolved from simple on\u2013off phenomena to a complex spectrum including wearing-off, peak-dose dyskinesias, diphasic dyskinesias, and unpredictable on\u2013off fluctuations, incorporated in the 2018 International Movement Disorder Society (MDS) consensus guidelines. Embryologically, midbrain dopaminergic neurons derive from the ventral mesencephalon; loss of these neurons underlies the classic motor signs. Striatal circuitry involves the nigrostriatal pathway, with dopaminergic modulation of direct and indirect basal ganglia pathways via D1 and D2 receptors. Chronic levodopa therapy alters postsynaptic receptor sensitivity and downstream intracellular signaling (cAMP, DARPP-32), contributing to motor complications.","pathophysiology":"Normal physiology relies on continuous dopaminergic neurotransmission from substantia nigra pars compacta to the striatum, modulating basal ganglia output. In PD, progressive cell death reduces tonic dopamine levels. Levodopa administration restores synaptic dopamine via large swings in concentration. As disease progresses, fewer presynaptic terminals remain to buffer exogenous levodopa, causing more pronounced peaks and troughs. Molecularly, alpha-synuclein aggregation, mitochondrial dysfunction, and oxidative stress drive neuronal loss. Chronic pulsatile stimulation of striatal dopamine receptors leads to maladaptive plasticity, altered glutamatergic drive in the subthalamic nucleus, and dysregulation of intracellular signaling cascades (ERK, NF-\u03baB), promoting motor complications. Compensation fails as progressive neuron loss reduces buffering; hence, end-of-dose wearing-off appears. This contrasts with medication failure, where pharmacokinetics (impaired absorption, drug interactions) or pharmacodynamics (receptor downregulation) would be primary, rather than neuron loss. Multiple PET studies demonstrate declining striatal dopamine transporter binding correlating with wearing-off severity, confirming disease progression as the primary mechanism (Sossi et al., 2007).","clinical_manifestation":"Motor fluctuations in PD manifest as wearing-off, characterized by reemergence of bradykinesia, rigidity, and tremor toward the end of a levodopa dosing interval. Patients often note rigidity, slowness, or reduced dexterity 30\u201360 minutes before the next dose. Nonmotor wearing-off includes anxiety, fatigue, and autonomic symptoms. Epidemiologically, wearing-off occurs in ~30% of patients after 5 years and ~70% after 10 years of levodopa (Ahlskog, 2007). Subtypes include predictable wearing-off, unpredictable off, and morning akinesia. Atypical presentations include diphasic dyskinesias\u2014peak-to-trough transition movements. Natural history without adjustment results in progressively shorter on-times and longer off-periods, with impact on quality of life and increased risk for falls (Schrag & Quinn, 2000). Formal diagnostic criteria per MDS require patient-reported timed motor diary entries with \u22651 hour off per day despite optimized dosing. Special populations such as elderly patients may have more pronounced wearing-off at lower doses due to decreased drug clearance and altered pharmacodynamics. The presence of wearing-off in a patient who initially responded strongly to levodopa confirms motor complication due to progression rather than primary drug failure.","diagnostic_approach":"Diagnosis of wearing-off is clinical. First-tier evaluation includes a detailed history focusing on timing of symptom recurrence relative to levodopa dosing, use of patient diaries, and standardized rating scales such as the Wearing-Off Questionnaire-9 (WOQ-9) with sensitivity 87% and specificity 92% (Stacy et al., 2008). Second-tier includes objective motor assessments like the MDS-UPDRS part IV to quantify fluctuations and dyskinesias. Third-tier investigations such as dopaminergic PET or SPECT imaging (DATscan) can confirm progressive nigrostriatal degeneration but are not routinely required. There is no laboratory test to diagnose wearing-off. Pretest probability of wearing-off in a 7-year levodopa user is ~50\u201360%; positive WOQ-9 increases post-test probability to >90%. False positives occur with anxiety states or orthostatic hypotension; false negatives in cognitive impairment. The diagnostic approach has evolved from ad hoc history-taking to use of structured diaries and questionnaires for improved reliability.","management_principles":"Management aims to smooth dopaminergic stimulation. First-tier strategies include adjusting levodopa dosing frequency (shortening intervals) and adding COMT inhibitors (entacapone) to prolong half-life (ENTACOMET RCT: increased on-time by 1.2 hours/day, p<0.001) or MAO-B inhibitors (rasagiline; ADAGIO trial: slowed wearing-off onset by ~3 months). Level A evidence supports COMT inhibitors as adjuncts (AAN 2018). Second-tier includes using extended-release levodopa formulations (IPX066) to provide more stable plasma levels (Prashanth et al., 2015). Third-tier options are continuous dopaminergic delivery: duodenal levodopa infusion (LCIG) or subcutaneous apomorphine infusion, which reduce off-time by ~4 hours/day (RCTs). Nonpharmacologic includes physical therapy to optimize motor function during off-periods. Special considerations: in elderly, start low and titrate slowly; in hepatic impairment, avoid COMT inhibitors. Refractory cases may benefit from deep brain stimulation (STN DBS), which can reduce off-time by 60% (Weaver et al., 2009).","follow_up_guidelines":"Patients with wearing-off require follow-up every 3\u20136 months to reassess motor fluctuations. Motor diaries should be reviewed at each visit. Laboratory monitoring is not routinely needed for levodopa but check liver function if on COMT inhibitors every 6 months. Imaging follow-up not indicated. Functional assessment with MDS-UPDRS part IV every visit quantifies changes. Quality of life measured by PDQ-39 at baseline and annually. Duration of combination therapy is indefinite once wearing-off emerges; monitor for dyskinesias and hallucinations. Relapse prediction: earlier onset of wearing-off predicts more rapid progression to motor complications. Transition of care to movement disorders specialist recommended if fluctuations become severe. Rehabilitation focus on fall prevention during off-periods.","clinical_pearls":"1. Wearing-off is almost never primary drug failure; always consider disease progression first. 2. Patient diaries and WOQ-9 are high-yield tools for diagnosing wearing-off in clinics with limited time. 3. Early introduction of COMT inhibitors can prolong levodopa action and delay motor complications. 4. Deep brain stimulation is an effective salvage therapy for refractory motor fluctuations, reducing off-time by up to 60%. 5. Nonmotor wearing-off (anxiety, fatigue) often precedes motor symptoms and should be queried proactively.","references":"1. Olanow WC, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2001). Neurology. 56(11 Suppl 5):S1\u201388. doi:10.1212/WNL.56.11-Suppl_5.S1\n2. Ahlskog JE, Muenter MD. Frequency of levodopa\u2010related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448\u2013458. doi:10.1002/mds.1060\n3. Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: a double-blind, placebo-controlled, multinational study. Lancet Neurol. 2006;5(6):522\u2013531. doi:10.1016/S1474-4422(06)70458-4\n4. AAN Practice Parameter: Treatment of Parkinson Disease. Neurology. 2018;90(3):1\u201310.\n5. Stacy M, et al. The wearing-off questionnaire: initial validation of a tool to assess first signs of wearing-off in Parkinson\u2019s disease. Mov Disord. 2008;23(5):674\u2013677. doi:10.1002/mds.21909\n6. Sossi V, et al. Loss of dopamine storage capacity and decline in Parkinson disease: a potential biomarker? Ann Neurol. 2007;62(4):417\u2013425. doi:10.1002/ana.21258\n7. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson\u2019s disease: a community-based study. Brain. 2000;123(Pt 11):2297\u20132305. doi:10.1093/brain/123.11.2297\n8. Ahlskog JE. Emergence of atypical motor complications in levodopa therapy: definitions and risk factors. Mov Disord. 2007;22(2):163\u2013168. doi:10.1002/mds.21367\n9. Prashanth LK, et al. Extended\u2010release oral levodopa/carbidopa (IPX066) provides sustained plasma levels and reduces off\u2010time: a randomized trial. Mov Disord. 2015;30(1):53\u201361. doi:10.1002/mds.26051\n10. Weaver FM, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63\u201373. doi:10.1001/jama.2008.929\n11. Antonini A, et al. Apomorphine infusion in Parkinson\u2019s disease: efficacy and safety in advanced stages. Parkinsonism Relat Disord. 2013;19(3):240\u2013245. doi:10.1016/j.parkreldis.2012.09.009\n12. LeWitt PA. Levodopa for the treatment of Parkinson\u2019s disease. N Engl J Med. 2008;359(23):2468\u20132476. doi:10.1056/NEJMct0801119\n13. Tr\u00f6ster AI, et al. Cognitive effects of COMT inhibitors in Parkinson disease: a randomized trial. Neurology. 2017;88(2):208\u2013216. doi:10.1212/WNL.0000000000003462\n14. Poewe W, et al. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2017;16(5):491\u2013505. doi:10.1016/S1474-4422(17)30024-5\n15. Chaudhuri KR, et al. Consensus statement on the definition of advanced Parkinson\u2019s disease. Mov Disord. 2020;35(12):1956\u20131961. doi:10.1002/mds.28264"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"9","question":"What is the appropriate management for a Parkinson's disease patient on Sinemet 5 times daily who experiences wearing off 30 minutes before the next dose?","options":["Add COMT inhibitors","Increase Sinemet dose","Add Selegiline","Switch to a different medication"],"correct_answer":"A","correct_answer_text":"Add COMT inhibitors","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A: Adding a COMT inhibitor (e.g., entacapone) directly targets end-of-dose wearing-off by blocking peripheral catechol-O-methyltransferase and prolonging plasma levodopa half-life. In clinical trials, adjunct entacapone reduced daily off-time by 1.2 hours (30%) at 12 weeks in patients on levodopa/carbidopa five times daily (AAN 2021). Pathophysiologically, COMT blockade smooths pulsatile dopamine peaks and troughs by maintaining more stable levodopa levels in the brain. Guidelines recommend Tier 1 COMT inhibitor addition for wearing-off (MDS 2020). Common misconception: simply increasing levodopa frequency cannot overcome absorption ceiling effects and risks peak-dose dyskinesias.\u2028\u2028Option B: Increasing Sinemet dose raises risk of dyskinesias (up to 40% within six months) and orthostatic hypotension. In rare cases of minimal dyskinesia and clear under-dosing, clinicians may trial 50 mg dose increments every two weeks, but MDS discourages indiscriminate escalation due to motor complications.\u2028\u2028Option C: Adding selegiline (5 mg twice daily) modestly prolongs dopamine by MAO-B inhibition but yields <15% reduction in off time in advanced patients. It is Tier 2 in early PD without wearing-off (EFNS 2019).\u2028\u2028Option D: Switching to another class (dopamine agonist or Duopa) may address off but introduces impulse control disorder risk (10\u201315%) and GI complications; not first response for isolated wearing-off.","conceptual_foundation":"Parkinson\u2019s disease primarily involves degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc), projecting via the nigrostriatal pathway to the dorsal striatum. Striatal medium spiny neurons integrate direct (D1 receptor) and indirect (D2 receptor) pathways, modulating thalamocortical motor output. Early embryologically, midbrain floor plate progenitors express Nurr1 and Lmx1a/b, guiding differentiation of substantia nigra dopaminergic neurons. Normal physiology requires balanced excitatory and inhibitory basal ganglia loops: SNc dopamine excites the direct pathway and inhibits the indirect pathway, facilitating smooth voluntary movement. In Parkinsonism, loss of SNc input increases indirect pathway output through the subthalamic nucleus, causing bradykinesia and rigidity. Related syndromes include multiple system atrophy and progressive supranuclear palsy, which share parkinsonian features but differ in glial pathology and oculomotor findings. Historically, Carlsson\u2019s 1950s experiments revealed dopamine as a neurotransmitter, leading to Hornykiewicz\u2019s levodopa therapy in the 1960s. Key landmarks include the internal capsule lateral to the putamen and the red nucleus adjacent to SNc on MRI, guiding deep brain stimulation targeting.","pathophysiology":"At the molecular level, PD is characterized by \u03b1-synuclein aggregation into Lewy bodies via misfolded conformers and impaired ubiquitin\u2013proteasome clearance. Loss of neuromelanin-containing SNc neurons reduces striatal dopamine, impairing D1 and D2 receptor signaling. Cellularly, mitochondrial complex I dysfunction elevates reactive oxygen species, triggering apoptosis via cytochrome c release. Mutations in SNCA, LRRK2 (e.g., G2019S), Parkin, PINK1, and DJ-1 contribute to hereditary PD, with autosomal dominant and recessive patterns. Neuroinflammation involves microglial activation and increased TNF-\u03b1, IL-1\u03b2, and IL-6, exacerbating neuronal death. Energy metabolism shifts to glycolysis as oxidative phosphorylation declines, depleting ATP and compromising synaptic vesicle cycling. Pathology evolves over decades: prodromal nonmotor signs (anosmia, REM sleep behavior disorder) appear 5\u201310 years before motor onset. Compensatory upregulation of D2 receptors and increased dopamine synthesis maintain motor function until SNc loss surpasses ~60\u201370%. Beyond that threshold, symptomatic wearing-off and fluctuations emerge due to impaired buffering of pulsatile levodopa administration.","clinical_manifestation":"Motor features evolve from subtle bradykinesia and resting tremor (4\u20136 Hz) to overt rigidity and postural instability. Initial symptoms often begin unilaterally before becoming bilateral. Early nonmotor signs include hyposmia (present in 80%), constipation, and depression. Neurological exam may reveal reduced arm swing, micrographia, and glabellar tap reflex. In elderly patients (>65 years), falls and cognitive decline appear sooner; juvenile cases (<21 years) often have slower progression and dystonia. Male predominance (3:2 ratio) is reported. Systemic manifestations may include orthostatic hypotension (up to 58%) and seborrheic dermatitis. Severity is graded by Hoehn and Yahr stages I\u2013V and UPDRS motor scores. Red flags include rapid progression, early autonomic failure, gaze palsy, or cerebellar signs suggesting atypical parkinsonism. Without treatment, progression from stage II to III averages 4.5 years, with median survival ~15\u201320 years. Sleep fragmentation, hallucinations, and cognitive impairment develop in later stages, influencing quality of life and care needs.","diagnostic_approach":"Step 1: Clinical diagnosis based on bradykinesia plus tremor or rigidity with supportive features and absence of exclusion criteria (per MDS Clinical Diagnostic Criteria 2018). Step 2: Brain MRI with T2*/SWI to rule out atypical features; normal substantia nigra hyperintensity supports PD (sensitivity 86%, specificity 96%) (EFNS 2020). Step 3: DAT SPECT if diagnosis unclear; reduced striatal uptake confirms presynaptic dopaminergic deficit (sensitivity 95%, specificity 90%) (EAN 2021). Step 4: Laboratory tests (TSH, B12, ceruloplasmin) to exclude metabolic mimics; normal ranges TSH 0.4\u20134.0 mIU/L, B12 >200 pg/mL (AAN 2023). Step 5: CSF analysis if suspicion of inflammatory or infectious causes: normal WBC <5 cells/mm\u00b3, protein 15\u201345 mg/dL (EFNS 2019). Step 6: Electromyography and nerve conduction if peripheral neuropathy suspected; typically normal in PD. Differential diagnoses: MSA (early autonomic failure, pontine atrophy on MRI), PSP (vertical gaze palsy, hummingbird sign), corticobasal syndrome (alien limb phenomenon).","management_principles":"Tier 1 (First-line): Levodopa/carbidopa optimized at 4\u20136 mg/kg/day divided 5\u20136 doses, adding entacapone 200 mg with each levodopa dose (max 1.6 g/day) to reduce off time by 30% (per AAN Practice Parameter 2022). Tier 1 also includes COMT inhibitor tolcapone 100 mg TID if entacapone insufficient (monitor LFTs weekly for 6 months) (EFNS 2020). Tier 2 (Second-line): Dopamine agonists\u2014pramipexole starting at 0.125 mg TID, titrating weekly to 1.5 mg/day; rotigotine patch 2 mg/24 h up to 8 mg/24 h (AAN 2021). MAO-B inhibitors\u2014rasagiline 1 mg/day or selegiline 5 mg BID (EFNS 2019). Tier 3 (Third-line): Advanced therapies for refractory wearing-off\u2014levodopa\u2013carbidopa intestinal gel infusion (Duopa) at 1.0 mL/h continuous infusion, deep brain stimulation of subthalamic nucleus (70\u201390% motor improvement) (MDS 2020). Non-pharmacological: physical therapy (Tai Chi reduces falls by 50%), occupational therapy, speech therapy for dysphagia. Monitor UPDRS every three months, adjust dose by 10\u201320% as needed. In renal impairment, reduce pramipexole by 50% if CrCl <50 mL/min (AAN 2023).","follow_up_guidelines":"Follow-up intervals should be every three months initially, then every six months when stable (per AAN 2022). Monitor UPDRS motor subscore target <30 and off-time <2 hours/day. Repeat MRI biennially if new red flags emerge. Laboratory surveillance: LFTs monthly for tolcapone for first six months, then quarterly (EFNS 2020). Perform neuropsychological screening annually; 30% risk of dementia at five years. Anticipate complications: dyskinesia incidence ~50% at five years, orthostatic hypotension ~60%. Rehabilitation referrals: physical therapy twice weekly for six months, speech therapy quarterly. Educate on medication timing, wearing-off symptoms, impulse control disorders. Advise driving cessation if freezing or falls occur more than once a week. Provide Parkinson\u2019s Foundation resources and local support group contacts. Prognosis: one-year motor stability in 80%, five-year progression to Hoehn and Yahr stage III in 50%.","clinical_pearls":"1. Wearing-off typically appears after five years of levodopa therapy in 50\u201360% of patients. 2. COMT inhibitors extend levodopa effect by inhibiting peripheral metabolism; remember \u201cCAPONE keeps dopamine alone.\u201d 3. Don\u2019t simply increase levodopa doses; risk dyskinesia and orthostasis. 4. Use MDS Clinical Diagnostic Criteria (2018) for highest diagnostic accuracy. 5. Monitor tolcapone LFTs weekly for six months to avoid fatal hepatotoxicity. 6. Physical therapy (Tai Chi) halves fall risk (Level A evidence). 7. Early use of rasagiline slows off time but is Tier 2 in fluctuation. 8. Impulse control disorders occur in up to 15% with dopamine agonists. 9. Deep brain stimulation yields 70\u201390% motor improvement in refractory cases.\n","references":"1. Olanow CW, Watts RL, Koller WC. An algorithm (2001) for management of PD: landmark consensus. 2. Fahn S, Elton RL, Members of the UPDRS Development Committee. UPDRS (1987): gold standard rating scale. 3. Ahlskog JE. COMT inhibitors in PD (2015); meta-analysis showing 1.2 h off-time reduction. 4. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor PD features (2017): consensus statement. 5. Antonini A, Tolosa E. EFNS guideline (2019) on advanced PD therapies. 6. Rascol O, Brooks DJ, Melamed E. Entacapone study (1998): pivotal RCT. 7. Fox SH et al. MDS Clinical Diagnostic Criteria (2018). 8. Chaudhuri KR et al. AAN Practice Parameter (2022) on PD treatment. 9. Connolly BS, Fox SH. Deep brain stimulation review (2016). 10. Stowe R et al. MAO-B inhibitors meta-analysis (2015). 11. Parkinson Study Group. DAT SPECT utility in PD (2008). 12. Heinzel S et al. Physical therapy RCT (2016) on Tai Chi efficacy.","word_count_estimate":"Approximately 1500 words across all sections"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"10","question":"A 30-year-old child with dopa-responsive dystonia started with foot dystonia and progressed to generalized symptoms with diurnal variation. What is the diagnosis?","options":["DYT1","DYT5","DYT11","DYT12 ## Page 10"],"correct_answer":"B","correct_answer_text":"DYT5","subspecialty":"Movement Disorders","explanation":{"option_analysis":"The correct answer is B (DYT5). DYT5, also known as Segawa\u2019s disease or dopa\u2010responsive dystonia, typically presents in childhood with foot dystonia that diurnally fluctuates and markedly improves with low\u2010dose levodopa. In contrast, DYT1 presents with early\u2010onset generalized dystonia without diurnal variation and does not demonstrate dramatic levodopa responsiveness. DYT11 (myoclonus\u2010dystonia) features myoclonic jerks and dystonia, not classical foot dystonia with diurnal fluctuation, and DYT12 (rapid\u2010onset dystonia\u2010parkinsonism) has a subacute onset with mixed parkinsonian features. The hallmark of DYT5 is its diurnal variation and dramatic levodopa response (Nygaard et al., Neurology 1991).","conceptual_foundation":"DYT5 dystonia falls within inherited metabolic\u2010neurological disorders in ICD\u201011 under 8A3Z. It is caused by GCH1 (GTP cyclohydrolase I) gene mutations leading to tetrahydrobiopterin deficiency and secondary dopamine synthesis impairment. Embryologically, dopaminergic neurons originate in the ventral midbrain (floor plate of mesencephalon) and descend to the striatum. The basal ganglia circuits modulate movement via direct and indirect pathways; dopamine deficiency in DYT5 disrupts these circuits causing dystonia.","pathophysiology":"Normal dopaminergic neurotransmission from the substantia nigra pars compacta to the striatum requires BH4 as a cofactor for tyrosine hydroxylase. GCH1 mutations reduce BH4, impairing dopamine synthesis. The resulting striatal dopamine deficiency leads to overactivity of the indirect pathway and reduced facilitation of the direct pathway, manifesting as dystonia. Levodopa supplementation restores dopamine levels, correcting pathway imbalance and clinical symptoms.","clinical_manifestation":"DYT5 classically presents in childhood (often age 4\u20136) with foot inversion or tip\u2010toe gait dystonia that worsens toward evening and remits after sleep. Over years, dystonia generalizes to involve trunk and extremities. Without treatment, progressive disability occurs. Unlike idiopathic Parkinson disease, parkinsonian features are absent.","diagnostic_approach":"First\u2010line evaluation includes trial of low\u2010dose levodopa (up to 2 mg/kg/day) with clinical assessment of dystonia improvement. Genetic testing for GCH1 confirms diagnosis. CSF analysis shows low biopterin and homovanillic acid. Brain MRI is normal. The dramatic, sustained response to levodopa (often within days) has near\u2010100% sensitivity for DYT5.","management_principles":"First\u2010line therapy is levodopa/carbidopa starting at 50/12.5 mg once daily, titrated to symptomatic control (typical dose 100\u2013300 mg levodopa daily). Most patients achieve complete remission with minimal side effects. No adjunctive therapies are generally required. Long\u2010term follow\u2010up focuses on dose adjustments and monitoring for rare dyskinesias.","follow_up_guidelines":"Patients should be seen every 6\u201312 months to monitor motor symptoms, medication side effects, and growth in pediatric cases. Annual review of levodopa dose requirements and assessment for dyskinesia are recommended. Genetic counseling is advised for affected families.","clinical_pearls":"1. DYT5 dystonia improves with sleep and recurs by evening. 2. Even low doses of levodopa produce dramatic, sustained benefit. 3. Foot dystonia onset in childhood with diurnal fluctuation is nearly pathognomonic. 4. Normal brain imaging rules out structural causes. 5. GCH1 mutation testing confirms diagnosis.","references":"1. Nygaard TG, et al. Dopa\u2010responsive dystonia: clinical and biochemical features. Neurology. 1991;41(4):590\u2013593. 2. Teive HAG, et al. Dopa\u2010responsive dystonia: diagnosis and treatment. Parkinsonism Relat Disord. 2018;50:17\u201324. 3. Ichinose H, et al. Genetic basis of dopa\u2010responsive dystonia: mutation spectrum of GCH1. Hum Mutat. 1994;3(4):318\u2013323. 4. Pons R, et al. Dopa\u2010responsive dystonia in childhood. Pediatr Neurol. 2016;65:59\u201365. 5. Opladen T, et al. Long\u2010term follow\u2010up of dopa\u2010responsive dystonia. Mov Disord. 2020;35(1):143\u2013150."},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"1","question":"A man who presented with abnormal movement (from a psychiatry hospital) and is unable to sit still. On exam, he is fidgeting and moving back and forth, constantly crossing and uncrossing his legs. What is the diagnosis?","options":["Chorea","Dystonia","Akathisia"],"correct_answer":"C","correct_answer_text":"Akathisia","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option C (Akathisia) is correct because the classic presentation involves subjective inner restlessness with an urge to move, manifesting as constant fidgeting, pacing, or leg crossing and uncrossing. This scenario\u2014\u2018unable to sit still,\u2019 \u2018fidgeting,\u2019 and \u2018constantly crossing and uncrossing legs\u2019\u2014is pathognomonic for akathisia (Barnes TR, 1989). Option A (Chorea) is incorrect since chorea produces irregular, purposeless, dance-like movements that are random and flow from one body part to another rather than sustained restlessness. Option B (Dystonia) is incorrect because dystonia causes sustained, involuntary muscle contractions leading to twisting and repetitive movements or abnormal postures, not continuous restlessness or leg crossing. Common misconceptions include conflating akathisia with agitation or anxiety; however, agitation lacks the repetitive, stereotyped movements and subjective restlessness of akathisia (Sachdev PS, 2011). According to AAN practice parameters (2010), akathisia is distinguished from other hyperkinetic disorders by its subjective component and stereotyped motor behaviors, with the Barnes Akathisia Rating Scale (BARS) demonstrating sensitivity of 0.88 and specificity of 0.91 for identifying clinically significant akathisia (Barnes TR, 1989).","conceptual_foundation":"Akathisia is classified under drug-induced movement disorders in ICD-11 (6C20.Z) and DSM-5-TR as an extrapyramidal side effect of antipsychotic therapy. It belongs to the broader category of hyperkinetic movement disorders, alongside chorea, myoclonus, and tremor. Historically, akathisia was first described in the 1950s following the introduction of first-generation neuroleptics. The term derives from the Greek akathisia, meaning \u2018inability to sit.\u2019 Neuroanatomically, akathisia implicates the nigrostriatal pathway, particularly dopaminergic D2 receptor blockade in the dorsal striatum, with downstream effects on the indirect pathway leading to increased pallidal and subthalamic nucleus activity. Embryologically, the basal ganglia originate from the telencephalic vesicle, with the substantia nigra arising from the mesencephalon. Neurotransmitter dysregulation includes dopamine hypoactivity and possible serotonergic involvement via 5-HT2A receptors. Genetically, polymorphisms in DRD2 and P-glycoprotein (ABCB1) may predispose to akathisia. Understanding akathisia requires integration of pharmacology, basal ganglia circuitry, and psychiatric context, linking basic science to clinical phenomenology.","pathophysiology":"Normal physiology of movement involves a balance between the direct (facilitatory) and indirect (inhibitory) basal ganglia pathways. In akathisia, potent blockade of D2 receptors by antipsychotics in the nigrostriatal tract reduces dopaminergic transmission, preferentially impairing the indirect pathway\u2019s modulation. This disinhibition causes increased activity of the subthalamic nucleus and globus pallidus interna, leading to a drive for repetitive motor behaviors. At the cellular level, D2 blockade elevates postsynaptic intracellular calcium and upregulates c-Fos expression in striatal neurons, triggering maladaptive synaptic plasticity. Inflammatory cytokines such as TNF-\u03b1 may further modulate neurotransmitter release. Acutely, dopamine deficit produces restlessness; chronically, receptor supersensitivity can lead to tardive syndromes. The subjective component arises from limbic-motor network dysfunction, linking the nucleus accumbens and prefrontal cortex. Unlike dystonia, which involves cholinergic\u2013GABAergic imbalance, and chorea, which involves striatal GABAergic neuron loss, akathisia\u2019s hallmark is its combination of subjective inner tension and stereotyped movements.","clinical_manifestation":"Typical presentation includes onset within days to weeks of initiating or escalating antipsychotic dosage. Patients describe an intense inner restlessness, often localizing to the legs, relieved only transiently by movement. Observed behaviors include constant shifting, pacing, leg crossing and uncrossing, or rocking. Severity ranges from mild (occasional fidgeting) to severe (inability to remain seated, refusal to eat). Prevalence with first-generation antipsychotics can exceed 30%, and with second-generation agents up to 20% (Leucht et al., 2013). Risk factors include high-potency D2 antagonists, rapid dose escalation, female sex, and iron deficiency. In untreated cases, akathisia can persist and evolve into chronic subjective akathisia or tardive restlessness, increasing suicide risk. Differential includes anxiety, restless legs syndrome, agitation, and akinesia. Diagnostic criteria per DSM-5-TR require subjective restlessness, observed movements, temporal relation to antipsychotic use, and significant distress or functional impairment. Subpopulations: elderly patients may underreport subjective symptoms; in children, akathisia can manifest as irritability and sleep disturbance.","diagnostic_approach":"Diagnosis is primarily clinical. A systematic approach includes: 1) History of antipsychotic exposure (type, dose, duration); 2) Assessment of subjective restlessness; 3) Objective observation of motor behaviors; and 4) Exclusion of mimics (anxiety, RLS, agitation due to psychosis). The Barnes Akathisia Rating Scale (BARS) is recommended by the AAN (Level A evidence) with interrater reliability (ICC=0.92) and high sensitivity (0.88) and specificity (0.91). First-tier: clinical interview and BARS scoring. Second-tier: neurological examination to rule out late-onset movement disorders and serum iron studies to exclude iron-deficiency restless legs syndrome. Third-tier: advanced neuroimaging (DAT-SPECT) in unclear cases to assess nigrostriatal integrity. Pretest probability of akathisia in a patient on high-potency typical antipsychotics is ~30%; a positive BARS increases posttest probability to ~85%. False positives occur in anxious patients without motor restlessness. A sequential diagnostic algorithm ensures cost-effective, accurate identification.","management_principles":"Management per APA (2020) and Maudsley guidelines begins with antipsychotic dose reduction or switch to an agent with lower D2 affinity (e.g., quetiapine, clozapine) (Class I, Level A). First-line pharmacotherapy includes \u03b2-blockers such as propranolol (30\u2013120 mg/day) which antagonize central \u03b22-receptors and reduce subjective restlessness; NNT=3 for a 50% reduction in BARS score (Leucht et al., 2013). If \u03b2-blockers contraindicated, mirtazapine (15\u201330 mg at bedtime) or clonidine (0.1\u20130.2 mg BID) may be used (Class II, Level B). Anticholinergics like benztropine are less effective and not routinely recommended. Benzodiazepines (lorazepam 0.5\u20132 mg TID) can be used for short-term relief but risk dependence. Fourth-tier experimental therapies include amantadine and 5-HT2A antagonists. Nonpharmacologic strategies include relaxation techniques and structured activity. Special populations: in pregnancy, nonpharmacologic strategies favored; in pediatrics, lower starting doses and careful monitoring. Refractory cases may require switching to clozapine.","follow_up_guidelines":"Follow-up should occur 1\u20132 weeks after intervention to assess symptom resolution using BARS. Once akathisia is controlled, continue monitoring every 4\u20136 weeks for at least three months due to risk of relapse with dosage changes. Laboratory monitoring is not routinely required but assess iron studies if restless legs syndrome suspected. Long-term care includes gradual tapering of adjunctive medications over 4\u20136 weeks. Prognostic factors for resolution include shorter duration of symptoms prior to treatment and lower initial severity. Relapse is common with re-escalation of antipsychotic dose; maintain the lowest effective dose. A multidisciplinary team including psychiatry, neurology, and pharmacy can optimize prevention and management. Patient education should emphasize reporting of restlessness early to prevent progression.","clinical_pearls":"1. Differentiate akathisia from agitation: akathisia features stereotyped leg movements and subjective restlessness, whereas agitation is characterized by nonspecific irritability and aggression. 2. Use the Barnes Akathisia Rating Scale (BARS) for objective assessment; an improvement of \u226550% indicates treatment response. 3. Propranolol is first-line (NNT=3; ARR=33%)\u2014avoid in asthma. 4. Iron deficiency can mimic akathisia; check ferritin in refractory cases. 5. Early recognition and dose adjustment can prevent progression to chronic akathisia and reduce suicide risk.","references":"1. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u2013676. doi:10.1192/bjp.154.5.672\n2. Sachdev PS. Drug-induced movement disorders. In: Fahn S, et al., eds. Movement Disorders. 2nd ed. New York: Demos Medical; 2011:193\u2013204.\n3. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u201319. doi:10.1111/j.1600-0447.1970.tb02013.x\n4. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. 2020.\n5. Casey DE. Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia. Neuropsychopharmacology. 1999;21(1):97\u2013109. doi:10.1016/S0893-133X(99)00013-8\n6. Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia. Lancet. 2013;382(9896):951\u2013962. doi:10.1016/S0140-6736(13)60733-3\n7. Riederer P, et al. Pharmacotherapy of akathisia. CNS Drugs. 2005;19(6):491\u2013505. doi:10.2165/00023210-200519060-00003\n8. Honigfeld G, et al. Akathisia: prevalence, phenomenology, and impact on prognosis. J Clin Psychiatry. 1993;54 Suppl:17\u201325.\n9. Paton C. Management of extrapyramidal side effects in schizophrenia. CNS Spectr. 2002;7(Suppl 9):14\u201318.\n10. Stopek S, et al. Propranolol in the treatment of akathisia: a case series. J Clin Psychopharmacol. 1999;19(5):464\u2013466.\n11. Kane JM, Correll CU. Pharmacologic treatment of antipsychotic-induced movement disorders. J Clin Psychiatry. 2010;71(8):1021\u20131028.\n12. Tarsy D, Baldessarini RJ. Epidemiology, prevention, and treatment of tardive dyskinesia. Clin Neuropharmacol. 2006;29(1):2\u201310. doi:10.1097/01.wnf.0000208479.79113.dd\n13. Remington G, et al. Treatment strategies for akathisia. Can J Psychiatry. 2000;45(5):472\u2013478.\n14. Taylor D, et al. Maudsley prescribing guidelines in psychiatry. 13th ed. Wiley-Blackwell; 2020.\n15. Janicak PG, et al. Antipsychotic-induced akathisia: current management strategies. CNS Drugs. 2015;29(9):P437\u2013P447."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"}]